Human MnSOD and Cancer Research

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 18: Line 18:
SODs, in general, have also been used in response to the side effects of radiation therapy. Radiation and chemotherapy greatly increase the ROS load in both malignant and normal tissue. Although its greater in cancer cells there is still considerably toxicity in regular human tissue <ref name="Utilizing">PMID:30573187</ref>. One of the drugs being used is GC4419 which is a class of Mn (II) SOD, it is specific for the removal of superoxide and no other ROS <ref name="Utilizing">PMID:30573187</ref>. The reason this medication is thought to be protective of normal tissue is that in the differences in oxidative metabolism between the two types of cells <ref name="Utilizing">PMID:30573187</ref>. This toxicity has been found to be decreased by Superoxide dismutase which leads to improved patient recovery by aiding in the removal of ROS after treatment. Nevertheless, SODs have been shown in this type of therapy to aid in the treatment of other side effects like mucositis which are a result of the chemoradiation therapy <ref name="Utilizing">PMID:30573187</ref>. The shows the use of MnSOD in therapeutic strategies can lead to positive results for the patient. Using MnSOD to treat certain patients has shown to be quite effective with very promising results, however, the enzyme itself has a very short half-life of around six minutes <ref name="Azadmanesh">PMID:29385710</ref>. One of the ways they can increase the half-life is by using liposomal delivery which increases the half-life to four hours. Although it’s a large increase, the drawback is the MnSOD drugs must be administered regularly and often <ref name="Azadmanesh">PMID:29385710</ref>
SODs, in general, have also been used in response to the side effects of radiation therapy. Radiation and chemotherapy greatly increase the ROS load in both malignant and normal tissue. Although its greater in cancer cells there is still considerably toxicity in regular human tissue <ref name="Utilizing">PMID:30573187</ref>. One of the drugs being used is GC4419 which is a class of Mn (II) SOD, it is specific for the removal of superoxide and no other ROS <ref name="Utilizing">PMID:30573187</ref>. The reason this medication is thought to be protective of normal tissue is that in the differences in oxidative metabolism between the two types of cells <ref name="Utilizing">PMID:30573187</ref>. This toxicity has been found to be decreased by Superoxide dismutase which leads to improved patient recovery by aiding in the removal of ROS after treatment. Nevertheless, SODs have been shown in this type of therapy to aid in the treatment of other side effects like mucositis which are a result of the chemoradiation therapy <ref name="Utilizing">PMID:30573187</ref>. The shows the use of MnSOD in therapeutic strategies can lead to positive results for the patient. Using MnSOD to treat certain patients has shown to be quite effective with very promising results, however, the enzyme itself has a very short half-life of around six minutes <ref name="Azadmanesh">PMID:29385710</ref>. One of the ways they can increase the half-life is by using liposomal delivery which increases the half-life to four hours. Although it’s a large increase, the drawback is the MnSOD drugs must be administered regularly and often <ref name="Azadmanesh">PMID:29385710</ref>
-
Another project that was done regarding MnSOD and colon cancer. The research looked at Sirtuin 3, which is the predominant mitochondrial deacetylase that balances ROS concentration by the regulation of Mitochondrial proteins like MnSOD <ref name="SIRT3">PMID:29323702</ref>. The aim of the research was to identify what effect silencing SIRT3 had on the response of antioxidants, and whether this response improved the ability of the drug “Oxaliplatin” to treat colon cancer <ref name="SIRT3">PMID:29323702</ref>. The results for the knockdown of SIRT3 showed an increased number of ROS species due to the acetylation of MnSOD, which effectively deactivated MnSOD <ref name="SIRT3">PMID:29323702</ref>. This led to more apoptosis of cells due to more ROS and the presence of Oxaliplatin, which reduced the cellular viability (<ref name="SIRT3">PMID:29323702</ref>. Additionally, in another paper, researchers found that a small molecule is involved in the activation of SIRT3, this molecule called C12 binds to SIRT3 and from there SIRT 3 would '''<scene name='81/814062/Lys68/2'>Deacetylate the lys68</scene>''' residue on MnSOD <ref name="silencer">PMID:28711502</ref>. This activation would then allow the MnSOD to function to rid the cell of ROS <ref name="silencer">PMID:28711502</ref>. This is an important piece of information because it allows us to see how MnSOD is activated and deactivated in regard to the activation and knockdown of SIRT3. From this, they were able to determine a way to modify the structure of MnSOD to use it correctly for colon cancer therapies.
+
Another project that was done regarding MnSOD and colon cancer. The research looked at Sirtuin 3, which is the predominant mitochondrial deacetylase that balances ROS concentration by the regulation of Mitochondrial proteins like MnSOD <ref name="SIRT3">PMID:29323702</ref>. The aim of the research was to identify what effect silencing SIRT3 had on the response of antioxidants, and whether this response improved the ability of the drug “Oxaliplatin” to treat colon cancer <ref name="SIRT3">PMID:29323702</ref>. The results for the knockdown of SIRT3 showed an increased number of ROS species due to the acetylation of MnSOD, which effectively deactivated MnSOD <ref name="SIRT3">PMID:29323702</ref>. This led to more apoptosis of cells due to more ROS and the presence of Oxaliplatin, which reduced the cellular viability (<ref name="SIRT3">PMID:29323702</ref>. Additionally, in another paper, researchers found that a small molecule is involved in the activation of SIRT3, this molecule called C12 binds to SIRT3 and from there SIRT 3 would '''<scene name='81/814062/Lys68/4'>deacetylate the lys68</scene>''' residue on MnSOD <ref name="silencer">PMID:28711502</ref>. This activation would then allow the MnSOD to function to rid the cell of ROS <ref name="silencer">PMID:28711502</ref>. This is an important piece of information because it allows us to see how MnSOD is activated and deactivated in regard to the activation and knockdown of SIRT3. From this, they were able to determine a way to modify the structure of MnSOD to use it correctly for colon cancer therapies.

Revision as of 16:12, 29 April 2019

Human Manganese Superoxide Dismutase

Caption for this structure

Drag the structure with the mouse to rotate

References

  1. Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:http://dx.doi.org/10.1002/ijch.201300024
  2. 2.0 2.1 2.2 2.3 2.4 2.5 Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644
  3. 3.0 3.1 3.2 3.3 3.4 3.5 Borgstahl GE, Parge HE, Hickey MJ, Beyer WF Jr, Hallewell RA, Tainer JA. The structure of human mitochondrial manganese superoxide dismutase reveals a novel tetrameric interface of two 4-helix bundles. Cell. 1992 Oct 2;71(1):107-18. PMID:1394426
  4. 4.0 4.1 4.2 Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol. 2003 Oct 15;552(Pt 2):335-44. doi: 10.1113/jphysiol.2003.049478. PMID:14561818 doi:http://dx.doi.org/10.1113/jphysiol.2003.049478
  5. 5.0 5.1 5.2 5.3 5.4 5.5 Dhar SK, Batinic-Haberle I, St Clair DK. UVB-induced inactivation of manganese-containing superoxide dismutase promotes mitophagy via ROS-mediated mTORC2 pathway activation. J Biol Chem. 2019 Mar 11. pii: RA118.006595. doi: 10.1074/jbc.RA118.006595. PMID:30858178 doi:http://dx.doi.org/10.1074/jbc.RA118.006595
  6. 6.0 6.1 Church SL, Grant JW, Ridnour LA, Oberley LW, Swanson PE, Meltzer PS, Trent JM. Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):3113-7. PMID:8464931
  7. 7.0 7.1 7.2 7.3 Mapuskar KA, Anderson CM, Spitz DR, Batinic-Haberle I, Allen BG, E Oberley-Deegan R. Utilizing Superoxide Dismutase Mimetics to Enhance Radiation Therapy Response While Protecting Normal Tissues. Semin Radiat Oncol. 2019 Jan;29(1):72-80. doi: 10.1016/j.semradonc.2018.10.005. PMID:30573187 doi:http://dx.doi.org/10.1016/j.semradonc.2018.10.005
  8. 8.0 8.1 8.2 8.3 Torrens-Mas M, Hernandez-Lopez R, Oliver J, Roca P, Sastre-Serra J. Sirtuin 3 silencing improves oxaliplatin efficacy through acetylation of MnSOD in colon cancer. J Cell Physiol. 2018 Aug;233(8):6067-6076. doi: 10.1002/jcp.26443. Epub 2018 Mar , 6. PMID:29323702 doi:http://dx.doi.org/10.1002/jcp.26443
  9. 9.0 9.1 Lu J, Zhang H, Chen X, Zou Y, Li J, Wang L, Wu M, Zang J, Yu Y, Zhuang W, Xia Q, Wang J. A Small Molecule Activator of SIRT3 Promotes Deacetylation and Activation of Manganese Superoxide Dismutase. Free Radic Biol Med. 2017 Jul 12. pii: S0891-5849(17)30684-6. doi:, 10.1016/j.freeradbiomed.2017.07.012. PMID:28711502 doi:http://dx.doi.org/10.1016/j.freeradbiomed.2017.07.012

Proteopedia Page Contributors and Editors (what is this?)

Jared Harrison, Michal Harel

Personal tools